Full View

Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel …

Y Komaki, A Yamada, F Komaki, D Micic… - Alimentary …, 2017 - Wiley Online Library
Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …
被引用次数：129 相关文章

Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases

Y Komaki, A Yamada, F Komaki… - Alimentary …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel …

Y Komaki, A Yamada, F Komaki, D Micic, A Ido… - Alimentary …, 2017 - infona.pl
Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases …

Y Komaki, A Yamada, F Komaki, D Micic… - Alimentary …, 2017 - europepmc.org
Background Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …